Introduction: Psoriatic Arthritis (PsA) is a chronic inflammatory disease characterized by psoriasis, synovitis, enthesitis, spondylitis, and association with extra-articular manifestations and comorbidities. Treatment of PsA dramatically changed since the introduction of anti-TNF drugs which have shown to reduce the symptoms and signs of the disease and slow the radiographic progression. Despite the introduction of new molecules with different mechanisms of action, the role of anti-TNF in the treatment of all disease manifestations of this intriguing disease is still central. Areas covered: The aim of this paper is to review the role of anti-TNF drugs in the treatment of different disease domains in PsA (peripheral and axial joints, skin, enthesis, patient’s reported outcomes, extra-articular manifestations), reporting data from randomized clinical trials and observational studies. An extensive literature search was performed on PubMed, with no limits or filters. The following search terms were used: ‘anti-TNF’, ‘Psoriatic Arthritis’. Expert opinion: Despite the emergence of different new treatments, anti-TNF therapy remains central in the management of all disease domains in PsA patients.
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1080/1744666X.2020.1685382|
|Codice identificativo ISI:||WOS:000495406200001|
|Codice identificativo Scopus:||2-s2.0-85074844969|
|Titolo:||TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis|
|Appare nelle tipologie:||1.1 Articolo in rivista|